MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing circuit-specific pharmacotherapies for central nervous system disorders. The company focuses on neuropsychiatric conditions, including schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder. Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, currently in Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. A second candidate, ML-004, is a 5-HT1B/1D agonist being evaluated for social communication deficits in autism spectrum disorder. The company also maintains preclinical programs for hyperactivity and agitation-related disorders, including ML-009, ML-055, and ML-021. MapLight utilizes a discovery platform that combines technologies such as optogenetics, transcriptomics, and STARmap to identify neural circuits linked to disease. The company was founded by leaders in psychiatry and neuroscience research to address the lack of targeted treatments for debilitating brain disorders.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage maplightrx.com
Sector Healthcare IR page ir.maplightrx.com
Tags
neuropsychiatric disorders, schizophrenia, alzheimer's disease psychosis, autism spectrum disorder, muscarinic receptor agonists, circuit-specific pharmacotherapies, clinical-stage, central nervous system, ML-007C-MA, ML-007, ML-004, ML-009, ML-055, ML-021, ZEPHYR, VISTA, IRIS
Press page —

Metrics

Valuation  
Market cap $ 447.586M
Market cap (USD) $ 447.586M
P/E -0.43
PEG —
P/BV 1.00
P/S —
P/OCF -3.24
P/FCF -3.23
Dividend yield —
Turnover / mcap —
Returns  
ROE -56.2%
ROI -38.7%
ROIC -30.4%
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Assets 479.512M — — —
Net profit -161.152M — 0 0
Free cash flow -138.61M — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 17.57 — — —
P/FCF -5.58 — — —

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) 6.58M 5.8M
Cash and deposits (USD) 38.3M 46.7M
Right-of-use assets (USD) 6.35M 5.49M
Cash flow detail
Operating cash flow (USD) -78.8M -138M
Purchases of property, plant and equipment (USD) -770,000 -473,000
Change in payables (cash effect) (USD) -1.35M 1.38M
Share-based compensation (USD) 1.08M 36M
Free cash flow (OCF - PPE - intangibles) (USD) -79.6M -139M
Income detail
Research and development expense (USD) 68.5M 138M
Total comprehensive income (USD) -77.4M -162M
Comprehensive income to owners (USD) -77.4M -162M
Reported Mar 26, 2026 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 16, 2026, MapLight Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its voting common stock, par value $0.0001 per share (“Common Stock”), through or to the Agent (the “ATM Offering”). The ATM Shares will be offered and sold pursuant to a Registration Statement on Form S-3 filed by the Company on November 16, 2026 (the “Registration Statement”) and the prospectus related to the ATM Offering that forms a part of such Registration Statement (the “ATM Prospectus”). Pursuant to the ATM Prospectus, the Company may sell Common Stock having an aggregate offering price of up to $100,000,000. Subject to the terms and conditions of the Agreement, the Agent will use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon the Company’s instructions. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a commission of up to 3.0% of the aggregate gross sales price per share sold under the Agreement.

Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027

Enrollment ongoing in Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results now expected in 2028; ML-007C-MA holds FDA Fast Track designation in ADP

Ended the quarter with $463.4 million in cash, cash equivalents and investments, expected to fund operations through key clinical readouts and through 2028

SAN FRANCISCO and BOSTON, November 16, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market,” said Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight.

Oct 6, 2026

PDF Version

Award honors foundational discoveries in optogenetics and circuit mapping

These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery

SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics (Nasdaq: MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine. Dr. Deisseroth shares the honor with Peter Hegemann, Ph.D., of Humboldt University of Berlin, and Georg Nagel, Ph.D., of the University of Würzburg, for their discoveries concerning light-gated ion channels and optogenetics.

The Nobel Assembly recognized optogenetics for transforming scientists’ ability to study how nerve cells shape memories, feelings and behaviors in the living brain, laying the foundation for a new era in neuroscience. Over the past two decades, optogenetics has fundamentally advanced the understanding of the biological basis of behavior, cognition and neuropsychiatric disease.

Dr. Deisseroth’s academic breakthroughs enabled scientists to investigate causal relationships between specific neural circuits and behavior and inspired the founding of MapLight in 2018. MapLight translates insights from circuit neuroscience into a precision approach to drug discovery, using optogenetics and related tools to identify specific cell types and molecular targets linked to psychiatric and neurodevelopmental symptoms. The Company then develops oral small-molecule candidates designed to modulate disease-relevant circuit activity and provide potential therapeutic relief.

This approach underpins the translation of circuit biology into a diverse pipeline of early- and clinical-stage product candidates. The Phase 2 ZEPHYR study of ML-007C-MA, which evolved from optogenetic and other preclinical work at MapLight, recently met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in schizophrenia symptoms. Based on these results, MapLight announced its intention to engage with the FDA in an End-of-Phase 2 (EOP2) meeting and subsequently initiate a Phase 3 study in schizophrenia. Similarly, preclinical work leveraging optogenetics in models of autism informed the design and conduct of the Phase 2 IRIS study. Based on these results, MapLight announced its intention to engage with the FDA in an EOP2 meeting to discuss a planned Phase 3 program in irritability associated with autism.

“Optogenetics began as a way to ask a basic question: how does electrical activity in specific cells give rise to human behavior and emotion?” said Dr. Deisseroth. “Neuroscience has long needed a better understanding of the functional biology of neural circuits and the relationship between circuit dysfunction and disease. I am deeply grateful to the institutions, trainees, and colleagues that have enabled and supported my work over the years, and to Peter Hegemann and Georg Nagel for their foundational contributions. As a practicing psychiatrist, seeing these basic biological discoveries move from the lab into human clinical trials is the ultimate realization of this work.”

“On behalf of everyone at MapLight, congratulations to Karl on this monumental achievement,” said Christopher Kroeger, M.D., Chief Executive Officer of MapLight. “The Nobel recognition of Karl’s academic work is a triumph for basic science and underscores the transformative impact of understanding the brain at the circuit level. Karl’s Nobel work inspired MapLight’s founding premise: that understanding the causal relationship between neural circuits and behavior can enable a more precise approach to developing medicines for complex CNS disorders. We are incredibly proud to celebrate this extraordinary honor with Karl and to continue advancing the mission that his work inspired.”

Additional information about the 2026 Nobel Prize in Physiology or Medicine and the discoveries recognized by the Nobel Assembly is available in its official announcement.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

Prompts

MapLight Therapeutics, Inc. (ticker MPLT), listed in United States.

Company History

Date Change Detail
Sep 4, 2019 Renamed Alvarado Therapeutics, Inc. → MAPLIGHT THERAPEUTICS, INC.

ETFs Holding MapLight Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
TMED 0.40% 2,543 $ 91.141K Jun 30, 2026
TMSL 0.08% 63,511 $ 2.276M Jun 30, 2026
FSEG 0.04% 71 $ 2,544.64 Jun 30, 2026
RESM 0.01% 9 $ 322.56 Jun 30, 2026